310 related articles for article (PubMed ID: 21632885)
1. MicroRNAs as regulators of signal transduction in urological tumors.
Fendler A; Stephan C; Yousef GM; Jung K
Clin Chem; 2011 Jul; 57(7):954-68. PubMed ID: 21632885
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways.
Lichner Z; Mejia-Guerrero S; Ignacak M; Krizova A; Bao TT; Girgis AH; Youssef YM; Yousef GM
Am J Pathol; 2012 Apr; 180(4):1675-87. PubMed ID: 22326755
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
4. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.
Nogueira I; Dias F; Teixeira AL; Medeiros R
Pharmacogenomics; 2018 Feb; 19(3):249-261. PubMed ID: 29334302
[TBL] [Abstract][Full Text] [Related]
5. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.
Szabó Z; Szegedi K; Gombos K; Mahua C; Flaskó T; Harda K; Halmos G
Urol Oncol; 2016 Dec; 34(12):533.e21-533.e27. PubMed ID: 27427222
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.
Kurozumi A; Goto Y; Okato A; Ichikawa T; Seki N
J Hum Genet; 2017 Jan; 62(1):49-56. PubMed ID: 27357429
[TBL] [Abstract][Full Text] [Related]
7. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
[TBL] [Abstract][Full Text] [Related]
8. Functions of circular RNAs in bladder, prostate and renal cell cancer (Review).
Yang L; Zou X; Zou J; Zhang G
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649838
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
Catto JW; Alcaraz A; Bjartell AS; De Vere White R; Evans CP; Fussel S; Hamdy FC; Kallioniemi O; Mengual L; Schlomm T; Visakorpi T
Eur Urol; 2011 May; 59(5):671-81. PubMed ID: 21296484
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
11. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma.
He YH; Chen C; Shi Z
J Cell Physiol; 2018 Jun; 233(6):4458-4465. PubMed ID: 29215721
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Schubert M; Junker K; Heinzelmann J
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1673-95. PubMed ID: 26660324
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
14. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs in Renal Cell Carcinoma.
Sellitti DF; Doi SQ
Microrna; 2015; 4(1):26-35. PubMed ID: 26165467
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives.
Tsiakanikas P; Giaginis C; Kontos CK; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):981-991. PubMed ID: 30345829
[TBL] [Abstract][Full Text] [Related]
17. Feedback networks between microRNAs and epigenetic modifications in urological tumors.
Liep J; Rabien A; Jung K
Epigenetics; 2012 Apr; 7(4):315-25. PubMed ID: 22414795
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.
Bouhamdani N; Joy A; Barnett D; Cormier K; Léger D; Chute IC; Lamarre S; Ouellette R; Turcotte S
Int J Cancer; 2017 Aug; 141(4):778-790. PubMed ID: 28486780
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway.
Dias F; Teixeira AL; Santos JI; Gomes M; Nogueira A; Assis J; Medeiros R
Pharmacogenomics; 2013 Nov; 14(14):1793-803. PubMed ID: 24192126
[TBL] [Abstract][Full Text] [Related]
20. Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer.
Xu J; Li CX; Lv JY; Li YS; Xiao Y; Shao TT; Huo X; Li X; Zou Y; Han QL; Li X; Wang LH; Ren H
Mol Cancer Ther; 2011 Oct; 10(10):1857-66. PubMed ID: 21768329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
